Form 4: Arcutis Executive Sells Shares Under 10b5-1 Plan

Arcutis Biotherapeutics' SVP General Counsel, Masaru Matsuda, sold 1,657 shares of common stock at $30.23 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• On December 1, 2025, 1,657 shares of common stock were sold at a price of $30.23 per share.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on June 5, 2025, with a plan end date of September 4, 2026.
• Following this transaction, Masaru Matsuda beneficially owns 150,641 shares of Arcutis Biotherapeutics common stock.
• The reported beneficial ownership includes 822 shares acquired under the Arcutis Biotherapeutics, Inc. Employee Stock Purchase Plan on November 30, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned insider sale under a 10b5-1 plan, which is generally considered neutral. While it's a sale, the pre-planned nature mitigates immediate negative sentiment.

Positives

• The transaction was conducted under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent sale rather than an immediate reaction to new information.
• The reporting person still holds a significant number of shares (150,641), indicating continued alignment with shareholder interests.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

The 10b5-1 trading plan, under which this transaction occurred, is set to continue until September 4, 2026, indicating potential future planned transactions by the reporting person.

Industry Context

This Form 4 reports a routine insider transaction for a biotechnology company executive. Such pre-planned sales are common across industries and do not inherently signal specific industry trends or competitive shifts.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the pre-planned nature under a 10b5-1 plan suggests it's not based on new material non-public information. The remaining significant holding indicates continued alignment.
• Employees: No direct impact on employees, though the ESPP acquisition shows employee participation in stock ownership.

Next Steps

• The 10b5-1 trading plan is scheduled to continue until September 4, 2026, implying potential further planned transactions by the reporting person.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider stock sale by a corporate officer under a 10b5-1 trading plan. Such transactions are typically not indicative of a change in the company's fundamental outlook or the insider's long-term confidence. The sale volume is relatively small compared to the officer's remaining holdings. Therefore, it does not provide sufficient new information to warrant a change from a 'hold' position, assuming the investor's existing thesis on Arcutis Biotherapeutics remains unchanged.

Keywords

Arcutis Biotherapeutics, ARQT, Masaru Matsuda, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals